Oral administration of undenatured native chicken type II collagen (UC-II) diminished deterioration of articular cartilage in a rat model of osteoarthritis (OA)

C.M. Bagi † *, E.R. Berryman †, S. Teo †, N.E. Lane §

† Pfizer R&D, Comparative Medicine, Global Science & Technology, Groton, CT, USA
† Pfizer Consumer Healthcare, Madison, NJ, USA
§ Rheumatology and Aging Research, University of California at Davis School of Medicine, USA

SUMMARY

Objective: The aim of this study was to determine the ability of undenatured native chicken type II collagen (UC-II) to prevent excessive articular cartilage deterioration in a rat model of osteoarthritis (OA).

Methods: Twenty male rats were subjected to partial medial meniscectomy tear (PMMT) surgery to induce OA. Immediately after the surgery 10 rats received vehicle and another 10 rats oral daily dose of UC-II at 0.66 mg/kg for a period of 8 weeks. In addition 10 naïve rats were used as an intact control and another 10 rats received sham surgery. Study endpoints included a weight-bearing capacity of front and hind legs, serum biomarkers of bone and cartilage metabolism, analyses of subchondral and cancellous bone at the tibial epiphysis and metaphysis, and cartilage pathology at the medial tibial plateau using histological methods.

Results: PMMT surgery produced moderate OA at the medial tibial plateau. Specifically, the deterioration of articular cartilage negatively impacted the weight bearing capacity of the operated limb. Immediate treatment with the UC-II preserved the weight-bearing capacity of the injured leg, preserved integrity of the cancellous bone at tibial metaphysis and limited the excessive osteophyte formation and deterioration of articular cartilage.

Conclusion: Study results demonstrate that a clinically relevant daily dose of UC-II when applied immediately after injury can improve the mechanical function of the injured knee and prevent excessive deterioration of articular cartilage.

© 2017 The Author(s). Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
derivatives has been proposed to provide an adequate supply of nutrients required for cartilage repair and maintenance, improve and preserve the quality of the subchondral bone, and maintain the overall health of articular cartilage and subchondral bone. Over the past several years, a novel nutraceutical un-denatured type II collagen (UC-II) from chicken sternum cartilage has been studied in knee OA subjects. In vivo animal studies have reported that UC-II acts via specific regulatory T cells (Tregs) in the gut that migrate and concentrate in areas of inflammation upon stimulation, where they modulate local immune responses in an antigen-specific manner. Irrespective of the actual mechanism of action, collagen derivatives seem to improve the health of the articular cartilage and are safe for patients and therefore, should be considered for the prevention or treatment of OA as a sole therapy or in combination with other drugs. UC-II is derived from chicken sternum cartilage and is being marketed as a powdered, shelf-stable ingredient that at daily dose of 40 mg demonstrated clinical benefit by improving joint comfort, flexibility and mobility in OA patients.

Commonly used method to induce OA in rodents is unilateral medial meniscal tear (MMT) method resulting in rapid progression of degenerative changes in the articular cartilage of the medial tibial plateau including cartilage loss, subchondral bone formation and a loss of chondrocytes. The medial meniscotibial ligament anchors the medial meniscus to the medial tibial plateau to ensure high congruency between articular structures and the transfer of weight-bearing loads during locomotion. Because cartilage degeneration develops rather rapidly in rats, evaluating drugs aimed to protect articular cartilage using the MMT model is challenging. The partial medial meniscectomy tear (PMMT) method is deemed less invasive than the complete medial meniscectomy model and is thus considered a more suitable model to test the ability of UC-II products to prevent the deterioration of cartilage degeneration and improve the healing of damaged articular cartilage.

The present study tested the ability of undenatured native chicken type II collagen administered orally at the time of cartilage injury imposed by PMMT to prevent the excessive deterioration and improve the healing of articular cartilage.

Method

Test article

UC-II (InterHealth, Benicia, CA) consists of undenatured native chicken type II collagen (collagen 263.0 mg/g, hydroxyproline 32.9 mg/g). UC-II was manufactured from chicken sternum cartilage in a GMP-certified facility using a patented, low-temperature manufacturing process that ensures a particular level of UC-II content. UC-II was formulated in 0.5% methyl cellulose suspension and administered orally at 0.66 mg/kg/day for a period of 8 weeks. The rat 0.66 mg/kg/day UC-II dose was chosen because it is equivalent to the 40 mg/day UC-II used in clinical studies for a 60 kg human. The vehicle (0.5% methyl cellulose) was dosed orally at 5 ml/kg/day 7 days per week.

Animals and management

Male, 4 months old Lewis rats (Charles River Laboratories, Portage, MI) weighing 350 g at the beginning of the experiments were used in this study. All in vivo procedures were approved by the Institutional Animal Care and Use Committee (IACUC) and were performed in accordance with the US National Institutes of Health (NIH) Publication No. 85–23, revised 1996. The rats were pair housed in a temperature- and humidity-controlled room on a regular 12 h light/dark cycle. Irradiated LabDiet™ 5053 (Purina, Richmond, IN) and water were provided ad libitum. The animals were acclimated for 1 week and were allocated to study groups based on their body weight the day before surgery. A group of 10 naive rats were used as an intact control (Naive), and another 10 rats received sham surgery (Sham). Additionally, 20 rats received the PMMT surgery and were allocated to receive vehicle treatment (PMMT/veh) or a UC-II (PMMT/UC-II) treatment. The ARRIVE guidelines was used to ensure the rigor of study conduct ad reporting of the data.

Surgery

Surgery procedures were performed in a dedicated rodent surgical facility at Pfizer consisting of an animal preparation room and recovery room, surgeon preparation room and a surgical suite. To minimize variations, only one surgical research specialist with extensive experience in performing the PMMT surgery was certified by the Academy of Surgical Research and have had his surgical skills and knowledge assessed by a designated subject matter expert (Global Trainer or Global Surgeon) approved to perform surgery. The rats were induced and maintained under anesthesia using isoflurane. One dose each of carprofen (Pfizer Animal Health, Flushing, NY) and sustained-release buprenorphine (Zoopharm, Windsor, CO) were administered prior to surgery to ensure analgesia. Rats in the surgery groups were subjected to a partial medial meniscal tear (PMMT) surgery. Briefly, the medial meniscus was freed from its attachments to the margin of the medial tibial plateau prior to grasping the meniscus with forceps and transecting one-third of the medial collateral ligament and medial meniscus. In the sham surgery rats, the medial meniscus was visualized but not transected. The surgical incisions were closed in two layers using absorbable sutures.

Body weight, tissue collection and serum analyses

The body weight was measured twice weekly throughout the study. At the end of the study rats were euthanized and the entire right hind limb was harvested and carefully cleaned of the soft tissue. The limbs were wrapped in saline-soaked gauze and frozen at −20 °C for the ex vivo imaging and histological analyses of the tibial articular cartilage and bone. Blood was collected 8 weeks after surgery by jugular venipuncture under isoflurane anesthesia. The serum was stored at −20 °C and used to run the standard chemistry panel and biomarkers of bone and cartilage metabolism (see Supplemental Material for details).

Dynamic weight bearing (DWB)

DWB measurements were obtained before surgery, 6 days after surgery, 4 weeks after surgery and before euthanasia to assess the effects of surgery on the weight-bearing capacity of the hind and front legs. The DWB system (Bioseh, software 1.3.; Boulogne, France) is non-invasive method for measuring the weight and surface area of all four feet in a freely moving animal. Zone parameters were set for the analysis as follows: >2 g for one sensor or a minimum of three adjacent sensors >2 g (in order to be considered a valid zone). For each time segment that was stable for more than one second, zones that meet the above criteria were validated and assigned as either right or left and front or rear. A mean value for the weight and area of each zone were calculated over the entire testing period, based on the length of time of each validated segment. For each testing period, the animals were placed into the chamber and allowed 20–30 s to explore prior to data collection. The following parameters were measured over a 3-min
period: body weight (g), percentage of weight (% weight) and surface area (mm²) placed on the front left and right leg, both front legs combined, rear left and right leg and both rear legs combined.

**Radiology**

Following necropsy all knee joints were X-rayed with a Faxitron Model MX20 specimen scanner (Faxitron Bioptics LLC, Tucson, AZ) using an exposure time of 12–18 s at 31–35 kV. The radiographic images were used to inspect the bone samples for the presence of possible fractures or other bone abnormalities.

**Micro-computed tomography (μCT)**

The operated right knee joint was subjected to μCT utilizing a MicroCT 100® computed tomography system (Scanco Medical, Bassersdorf, Switzerland) to obtain a scout 3D image of the knee. The μCT images were used to ensure that the samples were reproducibly scanned and that the same region of interest (ROI) at the proximal tibial epiphysis and metaphysis for each specimen was analyzed.

The cancellous bone compartment of the metaphysis was analyzed 1 mm below the growth plate and extended 3 mm distally to include the metaphyseal secondary spongiosa. The cancellous bone was evaluated as previously described. In short, an ROI was drawn on 100 consecutive slices with a thickness of 1.0 mm that best represented the central segment of the tibia. The cancellous bone parameters included bone mineral density, tissue volume (bone and bone marrow), bone volume, bone volume/tissue volume ratio, bone surface, bone surface/bone volume, trabecular number, trabecular thickness, trabecular separation, connectivity diameter, and structural model index.

For subchondral bone analysis a 2.0 mm × 0.5 mm ROI was drawn on the pre-contrast images to include the cortical and cancellous subchondral bone underlying the articular cartilage as described earlier (for details see Supplemental Material).

**Histopathology**

After the knee joints were imaged with μCT, they were shipped to Histotox Labs, Inc. (Boulder, CO, USA), for tissue processing. The knee joints were placed in SurgiPath Decalci to HistoTox Labs, Inc. (Boulder, CO, USA), for tissue processing. The best represented the central segment of the tibia. The cancellous bone was evaluated as previously described. In short, an ROI was analyzed 1 mm below the growth plate and extended 3 mm distally measured along the surface (0% depth, where the cartilage on either side shows complete loss of cartilage) and at the level of the mid-zone (50% depth between surface and tidemark) as recommended earlier. The total cartilage degeneration with represents the total extent of the tibial plateau affected by any type of degeneration such as total loss or just fibrillation of matrix with or without chondrocyte death, thus this area is regularly larger than total cartilage loss parameter.

**Statistical analysis**

GraphPad Prism v.5.00 for Windows (GraphPad Software, USA, http://www.graphpad.com) was used for the statistical analysis. Data was expressed as mean ± 95% confidence interval where n = 10. Shapiro–Wilk test was used to test the normality of the data. One-way ANOVA followed by Dunnett’s multiple-comparison post-test was performed for the comparison of group mean differences against the Naïve group of rats. Student’s t test was done for unpaired comparison. Statistical significance was considered at P < 0.05.

**Results**

**Animals and serum assays**

After a transient loss of body weight due to sham-surgery and PMMT surgery, the body weight of all rats enrolled in the study increased by approximately 10% during the course of the study (Fig. 1(A)). Rats in the PMMT/veh and PMMT/UC-II groups developed OA, as evidenced by X-ray, μCT and histology. Surgery or treatment with vehicle and UC-II did not affect the serum chemistry parameters or biomarkers of bone and cartilage metabolism, although the rats from the PMMT/veh group exhibited the highest level of cartilage degradation marker CTX-II (P < 0.05 vs Naïve and Sham), whereas the PMMT rats treated with UC-II exhibited significantly (P < 0.05) lower CTX-II values compared to PMMT/veh controls (Table 1, Supplemental Material).

**DWB**

All operated rats shifted weight bearing toward the front legs in order to reduce the weight bearing on the operated limb. The weight-bearing capacity of the operated right hind leg was significantly (P < 0.05) lower in PMMT/veh rats than in rats in the Naïve group during the entire study, and significantly (P < 0.05) lower relative to Sham and PMMT/UC-II rats at the end of the study (Fig. 1(B)–(D)).

**Radiology**

The radiological appearance of the right knee did not differ between the Naïve and Sham rats. Osteophytes were evident on the 2D images in all PMMT/veh and all PMMT/UC-II animals. Rats in the PMMT/veh group exhibited less cancellous bone at the proximal tibial metaphysis relative to rats in Naïve and Sham, whereas the PMMT rats treated with UC-II exhibited significantly (P < 0.05) lower CTX-II values compared to PMMT/veh controls (Fig. 2).

**μCT evaluation**

Bone parameters of the cancellous bone (secondary spongiosa) at the proximal tibial metaphysis were affected by the PMMT surgery. PMMT surgery in the vehicle treated rats resulted in slightly lower bone mineral density (BMD), bone volume and trabecular number, and higher trabecular separation parameter relative to Naïve, Sham and PMMT/UC-II treated rats, although the change was
not significant (Fig. 2). In addition, Cathepsin K histochemistry showed more robust accumulation of the osteoclasts in the primary spongiosa below the growth plate cartilage of PMMT/veh rats relative to all other study groups which also indicate increased bone resorption and supports the μCT data (Fig. 3).

The subchondral bone parameters (bone area, bone volume and BMD) did not significantly differ between groups (Table 2, Supplemental Material). However, not statistically significant increase in the bone volume and BV/TV ratio indicated a mild thickening of the cortical layer in Zones 1 and 2 which is also visible in the 3D images of the tibial epiphysis of PMMT/veh and PMMT/UC-II rats. Additionally, osteophytes were clearly visible in both PMMT/veh and PMMT/UC-II rats, although their sizes varied (Fig. 4).

Cartilage damage and osteophytes were not evident in Naïve and Sham animals. However, significant articular cartilage damage was present in PMMT/veh rats relative to rats in Naïve and Sham group. Cartilage damage was less severe in PMMT/UC-II treated rats relative to Naïve and Sham controls, but also comparing to PMMT/veh group. In addition, the osteophytes in Zone 1 were significantly smaller in size in PMMT/UC-II rats compared to PMMT/veh rats (Fig. 5).

**Cartilage histology**

The thickness of the articular cartilage was similar in Naïve and Sham rats. PMMT/veh and PMMT/UC-II rats had damaged articular cartilage, with thickening of the cartilage in Zone 1 and a loss of cartilage matrix in Zone 2, but relatively intact cartilage in Zone 3 (Fig. 6). The 0.66 mg/kg dose of UC-II showed a modest effect in reducing damage to the cartilage as evidenced by less cartilage thickening in Zones 1, slightly thicker cartilage layer in Zone 2 and less variability in cartilage thickness in Zone 3. Also, rats in PMMT/UC-II group exhibited fewer fibrillations and less cartilage debris in the articular space relative to PMMT/veh rats (Fig. 6). In general, animals treated with the UC-II showed less variability in cartilage damage and better consolidated cartilage in Zones 1 and 3 relative to vehicle treated PMMT rats.

Loss of articular cartilage width was not evident in Naïve and Sham rats. However, width of articular cartilage loss was significantly lower in PMMT/veh rats relative to controls. Dosing with UC-II reduced cartilage damage in PMMT rats; however the efficacy of UC-II varied between animals (Fig. 7).

A loss of articular cartilage was not evident in the Naïve and Sham rats. As expected, articular cartilage loss in PMMT/veh rats was statistically significant relative to Naïve and Sham rats, and dosing of PMMT rats with UC-II attenuated this loss compared with the loss observed in the PMMT/veh rats not given the UC-II (Fig. 8).

Overall, the histological evaluation demonstrated that rats developed had PMMT-associated deterioration of their knee cartilage. Daily administration of UC-II reduced this PMMT-associated damage.

**Discussion**

This study was undertaken to assess the capacity of a UC-II to prevent the excessive deterioration of articular cartilage or to accelerate the recovery process following partial meniscectomy. The PMMT surgery results in the fractional displacement of the medial meniscus leading to shifts of the weight-bearing loads and to cartilage damage.

In our study, surgery resulted in transient decreases in body weight due to stress and postoperative pain. The overall increase in body weight was equal among all study animals, totaling 10% at the end of the 8-week study. Whereas the total weight bearing imposed on the rear legs in all rats slightly increased over time as the rats gained weight, the weight-bearing load placed on the right hind leg was lower in the PMMT rats relative to Naïve and Sham
Fig. 2. Top row shows the 2D μCT images of the right knee. Solid arrows indicate osteophyte formation in the PMMT and UC-II rats. Dotted arrow indicates less cancellous bone at proximal tibial metaphysis in PMMT controls. Bottom row shows the structural analysis of the cancellous bone at proximal tibial metaphysis. Although the differences between groups were not significant, the PMMT rats exhibited a slightly lower trabecular bone volume, decreased trabecular number and increased trabecular separation relative to Naïve and Sham rats. Treatment with UC-II helped maintenance of cancellous bone.
controls. Other studies have previously shown that osteoarthritic rats reduce weight bearing on the injured limb and shift their weight distribution to the contralateral limb. Patients with knee OA also exhibit gait asymmetries of the affected limb, such as reductions in the stance time and peak vertical force. Our data confirmed earlier findings that in contrast to bipeds, in which only option is to shift the weight to the contralateral limb, rats (quadrupeds) tend to alleviate mechanical imbalances associated with pain by shifting at least part of the weight burden onto their front legs, rather than simply overloading their contralateral limbs. Results from this study show that prompt treatment with UC-II at the time of surgery largely prevented the functional incapacity of injured limb to bear weight, allowing for subsequent close-to-normal biomechanics.

Physiologic mechanical loading plays a critical role in bone and cartilage physiology. Mechanical loading is well known to drive changes in skeletal remodeling to adjust the bone mass and architecture to meet mechanical demands. In rats, cancellous bone at the tibial metaphysis rapidly responds to changes in mechanical loading. Despite sedentary lifestyle of caged laboratory rats, the partial underloading of the operated leg was expected to activate bone resorption and cause a mild loss of cancellous bone in the tibia of PMMT rats. Concurrent to the bone loss, the underloading of weight-bearing bones initiates degenerative changes in the articular cartilage. Because the loss of bone in the operated limb was diminished by UC-II treatment, we hypothesized that the maintenance of knee functionality and load-bearing activity played a key role in preserving bone mass and structure in the tibia. Specifically, the maintenance of modest physical activity may indirectly help to limit damage of articular cartilage. Although the mechanisms that regulate the maintenance of bone and cartilage are different, compelling evidence indicates that mechanical

![Fig. 3. Shows the Cathepsin K staining of the cancellous bone at the growth plate cartilage. The PMMT rats showed more intense bone resorption relative to rats in the Naive, Sham, and UC-II groups, as evidenced by larger number and size of darkly stained osteoclasts.](image1)

![Fig. 4. Shows the 3D µCT images of the tibial epiphysis. Arrows indicate osteophyte formation in rats that received the PMMT surgery. The dotted arrow indicates the thicker subchondral bone in Zones 1 and 2 in PMMT and UC-II rats. The top view of the medial tibial plateau, depicted in the top left corner, shows the osteophyte formation.](image2)
Fig. 5. Shows the damage score of the articular cartilage and size of the osteophytes. Cartilage damage and osteophyte formation were not present in Naïve and Sham rats. Dosing with 0.66 mg/kg of UC-II prevented excessive cartilage deterioration and growth of large osteophytes.

Fig. 6. Shows a zonal analysis of the cartilage thickness evaluated at the medial tibial plateau. The thickening of the articular cartilage in Zone 1 and deterioration of articular cartilage in the Zones 1 and 2 is visible in operated rats. Dosing with UC-II was moderately effective in preventing deterioration of articular cartilage caused by the surgery. In addition, more cartilage debris and fibrillations (indicated by arrows) are evident in PMMT rats compared to UC-II dosed rats.
stimuli influence the crosstalk of signaling pathways, which plays a critical role in both cartilage and bone metabolism. Changes in local mechanical loads triggered by the deterioration of articular cartilage resulted in the accumulation of cortical bone beneath the damaged cartilage and the formation of osteophytes. The formation of osteophytes is believed to be an adaptation of the skeleton aimed to stabilize injured joints, accommodate new mechanical needs and prevent the further deterioration of cartilage. However, osteophytes can limit joint movements and cause pain, and their size is thought to be proportional to the severity of cartilage injury. Combination of radiology and histology techniques revealed that treatment with UC-II limits osteophyte size that can potentially help joint mobility and functionality.

The damage score and zonal quantification of total cartilage thickness (i.e., calcified plus noncalcified) identified a significant loss of articular cartilage in Zones 1 and 2 in PMMT rats. The width of cartilage matrix loss (%) demonstrated the extent of cartilage degeneration width parameter. Spontaneous healing of the articular cartilage was not evident in the PMMT rats, nevertheless numerous fibrillations and cell debris were frequently found on the histology images. In contrast, dosing of PMMT rats with UC-II limited the extent of cartilage damage and produced signs of recovery. Specifically, cartilage thickening in Zone 1 was reduced while the calcified and noncalcified cartilage layers in Zones 2 and 3 were not different in rats given UC-II compared to
PMMT controls. Likewise, the cartilage matrix loss width and cartilage degeneration width parameters were smaller in PMMT rats given UC-II compared to PMMT controls. Thus, the overall damage score index was favorable in PMMT rats given UC-II compound.

When applied at the time of injury, UC-II was moderately effective in preventing excessive degradation of the articular cartilage. A number of independent biomarkers (DWB, CTX-II, μCT and histology) showed that daily treatment with UC-II preserved joint functionality and curtailed excessive cartilage degradation. We hypothesize that several mechanisms most likely contribute to the efficacy of UC-II, including anti-inflammatory effects, the reduction of pain, the preservation of mechanical function and bone quality, and a supply of building material for cartilage repair. Our results support recent clinical data showing improved flexibility and pain reduction in arthritic patients receiving a 40 mg daily dose of UC-II. Disease-modifying therapies for OA are not currently available, and approximately 75% of OA patients regularly receive more than one symptomatic treatment. Other treatment modalities has been shown to reduce cartilage degradation, have no effect, or even to have a negative effect on articular cartilage in similar animal models of OA. Therefore, the complex nature of OA will most likely require simultaneous treatment with several lines of therapy to successfully treat the disease. The modeling of treatments will depend on the severity and duration of OA but should include ingredients such as UC-II.

Fig. 8. Shows the total and significant cartilage degeneration width parameters assessed on the Safranin O-stained sections. The PMMT-associated loss of the articular cartilage was partially prevented by UC-II. Red lines indicate the outer border (osteophyte side), and blue lines indicate the inner border (normal cartilage). Solid arrows indicate the total cartilage degeneration width; dotted arrows indicate significant cartilage degeneration width; yellow arrowheads indicate fibrillated cartilage and debris, which were primarily evident in the PMMT rats given no UC-II.
that have been demonstrated to be safe and capable of improving joint flexibility, joint pain and the overall health of bone and cartilage.

In general, studies aimed to test drug efficacy and treat OA face common challenges including choice of the disease model, proper study design to accommodate extensive in vivo procedures such as mechanical loading, and availability of cartilage and bone tissues that need different processing to allow imaging, histological and molecular analyses. This study was also limited by availability of relevant tissues needed to adequately address important questions regarding the true mechanism of action of UC-II in the articular cartilage, so methods such as immuno-histochemical staining and gene expression of proteins related to cartilage metabolism including collagen type II and X, MMP-13, SOX9, CCN2 were not performed. However, results from this study helped design of the follow-up studies that will include use of exercise and gait analysis to better address joint functionality and impact of disuse and load bearing on cartilage metabolism, use of radiolabeled compound to assess metabolism and tissue distribution of UC-II and use of adequate immunological, histochemical and molecular methods to address some of the lingering questions regarding mechanism of action of “slow-acting” product such as UC-II.

Authors’ contributions
CMB designed the study, interpreted the data and wrote the manuscript; EB did DWB, μCT and histology analyses consolidated all data and participated in writing the manuscript; ST contributed to study design, reviewed and helped interpretation of data, and participated in writing the manuscript, and NEL reviewed and helped interpretation of data, and participated in writing the manuscript.

Competing interest
The authors that are Pfizer employees have Pfizer stocks. Nancy Lane has no competing interest.

Role of the funding source
This study was supported by Pfizer Consumer Healthcare.

Acknowledgements
The authors thank David Zakur, Adam Murphy and Isabela Bagi for their excellent technical assistance. Special thanks go to Thomas P. Brown, DVM, MP, PhD for his excellent comments and suggestion while reviewing this manuscript. We would also like to acknowledge the excellent technical support from Bolder BioPATH, Inc. for preparing the histology slides.

Supplementary data
Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.joca.2017.08.013.

References
21. Lugo JP, Saiyed ZM, Lane NE. Efficacy and tolerability of an undenatured type II collagen (UC-II) supplement in...


